Adirondack Trust CO Vertex Pharmaceuticals Inc Transaction History

Adirondack Trust CO

$259 Million
Q3 2024

A detailed history of Adirondack Trust CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Adirondack Trust CO holds 449 shares of VRTX stock, worth $208,587. This represents 0.08% of its overall portfolio holdings.

Number of Shares

449

Previous 499 10.02%

Holding current value

$208,587

Previous $233,000 10.73%

% of portfolio

0.08%

Previous 0.1%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	SELL	$460.0 - $505.78 $23,000 - $25,289	-50 Reduced 10.02%	449 $208,000
Q2 2024 Jul 09, 2024	SELL	$392.81 - $485.53 $3,535 - $4,369	-9 Reduced 1.77%	499 $233,000
Q4 2023 Mar 29, 2024	SELL	$343.0 - $410.68 $3,087 - $3,696	-9 Reduced 1.74%	508 $206,000
Q3 2023 Oct 31, 2023	SELL	$338.18 - $362.46 $13,527 - $14,498	-40 Reduced 7.18%	517 $179,000
Q2 2023 Aug 09, 2023	SELL	$314.42 - $351.91 $3,144 - $3,519	-10 Reduced 1.76%	557 $196,000
Q1 2023 Apr 28, 2023	SELL	$283.23 - $323.1 $3,965 - $4,523	-14 Reduced 2.41%	567 $178,000
Q4 2022 Jan 13, 2023	BUY	$285.76 - $321.48 $30,290 - $34,076	106 Added 22.32%	581 $0
Q3 2022 Oct 13, 2022	BUY	$273.83 - $305.53 $15,882 - $17,720	58 Added 13.91%	475 $138,000
Q2 2022 Jul 06, 2022	BUY	$234.96 - $292.55 $30,309 - $37,738	129 Added 44.79%	417 $117,000
Q1 2022 Apr 05, 2022	BUY	$221.42 - $260.97 $50,040 - $58,979	226 Added 364.52%	288 $75,000
Q3 2021 Nov 16, 2021	BUY	$181.39 - $202.99 $6,711 - $7,510	37 Added 148.0%	62 $11,000
Q3 2019 Oct 09, 2019	SELL	$166.23 - $187.09 $13,298 - $14,967	-80 Reduced 76.19%	25 $4,000
Q3 2017 Oct 12, 2017	BUY	$148.13 - $162.24 $15,553 - $17,035	105	105 $16,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adirondack Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Adirondack Trust CO with notifications on news.

Account

Adirondack Trust CO Vertex Pharmaceuticals Inc Transaction History